Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated
